New Treatment Options for Relapsed/Recurrent DLBCL: Impact on Sequencing Therapeutic Choices

Medical experts highlight second-line options for treating patients with DLBCL.

Medical experts from various prestigious oncology institutions drive a conversation around referral patterns in the DLBCL treatment landscape.

An examination of results from key studies in the DLBCL landscape are conducted by Dr Fred Locke.

Multiple studies analyzing considerations for transplant-ineligible patients receiving second-line treatment with CAR T-cell therapy are discussed by key opinion leaders.

Dr Hunter discusses the decision making process around second-line therapies for transplant-ineligible patients, and further key clinical study data.

Bradley Hunter, MD, and Fred Locke, MD, and Elizabeth Budde, MD, PhD, share insights surrounding treatment considerations for CD19 targeting.

A panel of experts discuss current challenges for use of CAR T in R/R DLBCL.

A panel of experts discusses their individual approaches to bridging therapy in R/R DLBCL for patients eligible for CART

A panel of experts discuss risk of secondary malignancies in heavily pre-treated populations.

A panel of experts discuss the incidence, severity, and management of AEs associated with CAR Tcell therapy.

A panel of experts discuss the role of odronextamab.

A panel of experts discuss the current treatment landscape for bispecific antibodies and CAR T in R/R DLBCL.